RecruitingPhase 1NCT07516405
Safety and Tolerability Trial of Psilocybin in Healthy Older Adults
This study plans to learn more about the safety and tolerability of psychedelic administration (psilocybin) in healthy older adults ages 65-85. (The sponsor's summary, shortened.)
Eligibility and contacts on ClinicalTrials.govThe registry record
- Status
- Recruiting
- Phase
- Phase 1
- Conditions
- Healthy Volunteer; Older Adults (65-85 Years)
- Intervention
- Psilocybin (Usona Institute)
- Sponsor
- University of Colorado, Denver
- Ages
- 65 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Accepted
- Enrolment
- 40 people (planned)
- Start
- 1 April 2026
- Primary completion
- March 2028
- Registry last updated
- 16 September 2026
Sites (6)
- University of California San Francisco (UCSF) Department of Neurology, San Francisco, California, United States (recruiting)
- University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States (recruiting)
- Emory University Brain Health Center, Atlanta, Georgia, United States (recruiting)
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States (recruiting)
- University of Nebraska Medical Center, Omaha, Nebraska, United States (recruiting)
- New York University Langone Health, Center for Psychedelic Medicine, New York, New York, United States (recruiting)
How joining a trial works
- Free to take part
- Trials generally cost participants nothing for the study drug and the study visits, and some pay for travel or time. Check what a study covers on its registry page.
- Screened first
- Every study screens volunteers with questionnaires, medical history and often a physical and psychiatric check. Many people who apply are not enrolled.
- Eligibility is strict
- Common exclusions include a personal or family history of psychosis or bipolar disorder, some heart conditions, pregnancy and certain medications, which you may be asked to stop under medical supervision. Never stop a medication on your own to qualify.
- You may get a placebo
- Many trials compare psilocybin with a placebo or a low dose, and you may not be told which you had until the study ends.
- Contact the study team through the registry
- Each registry record lists the study contacts and sites. We do not republish personal emails or phone numbers; use the link on each trial page.
- Not medical advice
- This is a list of registry records, not a recommendation. Talk to your doctor before applying. Disclaimer · Safety and medications
Source: ClinicalTrials.gov API v2, U.S. National Library of Medicine, read 28 October 2026. Filter: overall status RECRUITING or NOT_YET_RECRUITING; an intervention named psilocybin, psilocin, COMP360 or CYB003. Refreshed weekly; a study's own registry page is always the current record.
Record read from ClinicalTrials.gov API v2, U.S. National Library of Medicine on 28 October 2026. All psilocybin trials